$BOLD
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Healthcare
Sector
Biotechnology
Industry
Zachary Hornby
CEO
64
Employees
$2.50
Current Price
$29.33M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 1 | 6 | $428,850.28 | 172,225 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 1 | 10 | $983,648.49 | 393,796 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 10 | $983,648.49 | 393,796 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 1 | 10 | $983,648.49 | 393,796 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 1 | 10 | $983,648.49 | 393,796 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | TANG KEVIN 10% Owner | Purchase | 9,821 | $2.49 | $24,454.29 | View Details |
| Jun 30, 2026 | TANG KEVIN 10% Owner | Purchase | 25,930 | $2.54 | $65,862.20 | View Details |
| Jun 30, 2026 | TANG KEVIN 10% Owner | Purchase | 100 | $2.50 | $250.00 | View Details |
| Jul 1, 2026 | TANG KEVIN 10% Owner | Purchase | 71,612 | $2.49 | $178,313.88 | View Details |
| Jun 26, 2026 | TANG KEVIN 10% Owner | Purchase | 134 | $2.54 | $340.36 | View Details |
| Jun 25, 2026 | TANG KEVIN 10% Owner | Purchase | 145,880 | $2.48 | $361,782.40 | View Details |
| Jun 26, 2026 | TANG KEVIN 10% Owner | Purchase | 75,047 | $2.55 | $191,369.85 | View Details |
| Jun 25, 2026 | TANG KEVIN 10% Owner | Purchase | 510 | $2.56 | $1,305.60 | View Details |
| Jun 29, 2026 | TANG KEVIN 10% Owner | Purchase | 63,985 | $2.47 | $158,042.95 | View Details |
| Jun 29, 2026 | TANG KEVIN 10% Owner | Purchase | 777 | $2.48 | $1,926.96 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: